Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Kasi on the Prognostic Value of ctDNA in CRC

October 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

October 23rd 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

Pivoting Away From the Biomarker Hunt in Gastric Cancer

October 23rd 2019

David H. Ilson, MD, PhD, discusses current treatment options for patients with gastric cancer, the challenges with the KEYNOTE-062 trial, and other immunotherapy agents coming down the pipeline.

Hepatocellular Carcinoma: Future Directions in Care

October 23rd 2019

Perioperative Approaches to HCC Management

October 23rd 2019

Optimal Sequencing of I/O Therapy in Liver Cancer

October 23rd 2019

I/O Combination Strategies in Hepatocellular Carcinoma

October 23rd 2019

Elevated AFP in Relapsed/Refractory Metastatic HCC

October 23rd 2019

Optimal Use of Second-Line TKIs in Hepatocellular Carcinoma

October 23rd 2019

Hepatocellular Carcinoma: Antiangiogenic Therapy Options

October 23rd 2019

Implications for I/O Therapy in the Treatment of HCC

October 23rd 2019

Liver Pathobiology's Role in Hepatocellular Carcinoma

October 23rd 2019

Dr. Benson on the Use of Genomic Testing in Newly Diagnosed mCRC

October 22nd 2019

Al B. Benson, MD, discusses the use of genomic testing in patients with newly diagnosed metastatic colorectal cancer.

Immunotherapy Combo Shows Signs of Efficacy in 2 HCC Settings

October 21st 2019

Using dual checkpoint inhibitors in patients with hepatocellular carcinoma is demonstrating activity with a manageable safety profile in both second-line and perioperative settings.

Atezolizumab/Bevacizumab Combo Improves Survival in Frontline HCC

October 21st 2019

The combination of atezolizumab and bevacizumab showed statistically significant and clinically meaningful improvements in both progression-free and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma who have not received prior therapy, meeting the coprimary endpoints of the IMbrave150 trial.

Final Thoughts on CCA

October 21st 2019

ClarIDHy Phase III Trial of Ivosidenib in CCA

October 21st 2019

Ivosidenib for Advanced IDH1-Mutated CCA

October 21st 2019

FGFR Inhibitors in Development for CCA

October 21st 2019

Infigratinib for CCA

October 21st 2019